These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 15711270

  • 1. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A, Spitz IM.
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [Abstract] [Full Text] [Related]

  • 2. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 3. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.
    Urol Int; 2006 Mar; 77(2):135-8. PubMed ID: 16888418
    [Abstract] [Full Text] [Related]

  • 4. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F.
    Prostate Cancer Prostatic Dis; 2009 Mar; 12(1):100-3. PubMed ID: 18574491
    [Abstract] [Full Text] [Related]

  • 5. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 6. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 01; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 7. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 01; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R, Lachance R, Dupont A, Labrie F.
    Clin Invest Med; 1986 Nov 01; 9(4):215-21. PubMed ID: 2433088
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
    Schlegel PN, Histrelin Study Group.
    J Urol; 2006 Apr 01; 175(4):1353-8. PubMed ID: 16515997
    [Abstract] [Full Text] [Related]

  • 12. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M.
    J Urol; 2005 Aug 01; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [Abstract] [Full Text] [Related]

  • 14. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep 01; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 15. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.
    N Engl J Med; 2009 Jun 11; 360(24):2516-27. PubMed ID: 19516032
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM, Chertin B, Lindenberg T, Farkas A.
    N Engl J Med; 1999 May 06; 340(18):1439. PubMed ID: 10328706
    [No Abstract] [Full Text] [Related]

  • 18. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I, Venho P, Jacobi G, Rannikko S.
    J Androl; 1991 May 06; 12(1):46-53. PubMed ID: 1901309
    [Abstract] [Full Text] [Related]

  • 19. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep 06; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 20. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
    Morote J, Planas J, Salvador C, Raventós CX, Catalán R, Reventós J.
    BJU Int; 2009 Feb 06; 103(3):332-5; discussion 335. PubMed ID: 19007366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.